Phase II trial of flavopiridol, a cyclin dependent kinase inhibitor, in untreated metastatic malignant melanoma

• Published in: Investigational new drugs Vol. 22; no. 3; pp. 315 - 322
• Main Authors: Burdette-Radoux, Susan, Tozer, Richard G, Lohmann, Reinhard C, Quirt, Ian, Ernst, D Scott, Walsh, Wendy, Wainman, Nancy, Colevas, A Dimitrios, Eisenhauer, Elizabeth A
• Format: Journal Article
• Language: English
• Published: United States Springer Nature B.V 01.08.2004
• Subjects: Adult; Aged; Anorexia - chemically induced; Antineoplastic Agents - adverse effects; Antineoplastic Agents - therapeutic use; Cancer therapies; Cell cycle; Chemotherapy; Creatinine; Cyclin-dependent kinases; Cyclin-Dependent Kinases - antagonists & inhibitors; Diarrhea; Diarrhea - chemically induced; Disease prevention; Fatigue - chemically induced; Female; Flavonoids - adverse effects; Flavonoids - therapeutic use; Granulocytes; Humans; Immunotherapy; Infusions, Intravenous; Kinases; Male; Maximum Tolerated Dose; Medical prognosis; Melanoma; Melanoma - drug therapy; Melanoma - pathology; Metastasis; Middle Aged; Nausea; Neoplasm Metastasis; Patients; Piperidines - adverse effects; Piperidines - therapeutic use; Skin cancer; Toxicity; Treatment Outcome; Vomiting - chemically induced
• ISSN: 0167-6997; 1573-0646
• DOI: 10.1023/B:DRUG.0000026258.02846.1c

To test the activity of the cyclin dependent kinase (cdk) inhibitor flavopiridol in malignant melanoma, a disease with frequent abnormalities of the cyclin dependent kinase system. Patients had histologically proven, unidimensionally measurable malignant melanoma, incurable by standard therapy. Prior adjuvant immunotherapy was allowed, but patients were otherwise untreated for advanced disease. Flavopiridol was administered at a dose of 50 mg/m(2) IV over 1 hour daily x 3 days every 3 weeks. Patients were assessed for response every 2 cycles. 17 patients were accrued over 5 months. No objective responses were documented in the 16 patients evaluable for response. Seven patients (44%) had stable disease after 2 cycles, with a median of 2.8 months (range 1.8-9.2). The most common treatment-related non-hematologic toxicities were diarrhea (82%), nausea (47%), fatigue (41%), anorexia (35%) and vomiting (29%). Most treatment-related toxicities were mild, except for diarrhea (grade 3 in 3 patients, grade 4 in 1 patient), nausea (grade 3 in 1 patient) and tumor pain (grade 3 in 1 patient). Hematologic toxicities were minimal, none worse than grade 2. Eighty-eight percent of patients received >/=90% planned dose intensity; 2 patients had dose reductions for gastrointestinal (GI) toxicity. Flavopiridol is well tolerated at the dose regimen used in this study, with an acceptable (primarily GI) toxicity profile. Although 7 of the 16 patients had stable disease ranging from 1.8 to 9.2 months in duration, there was no evidence of significant clinical activity in malignant melanoma by objective response criteria.